Posted by Michael Wonder on 20 Sep 2024
Abrysvo: Pfizer Canada's newly publicly funded vaccine a step towards national RSV prevention in older adults
19 September 2024 - Today, Pfizer Canada announced that Abrysvo has been selected as the publicly funded vaccine for the prevention of respiratory syncytial virus in older adults in Canada for 2024-2025.
Abrysvo is approved by Health Canada for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older.
